Clinical Research Details
Title:
CALGB 50303/CTSU50303 Phase III Randomized Study of R-CHOP v. Dose-Adjusted EPOCH-R with Molecular Profiling in Untreated De Novo Diffuse Large B-cell Lymphomas
Purpose:
The purpose of this study is to compare the effects of two treatments; R-CHOP with Dose-Adjusted EPOCH-R for untreated de novo DLBC lymphoma and to develop molecular predictor of outcome using molecular profiling.
Study Number:
109312
Number of Patients:
478
Elgibility:
Adults (> 18) with histologically documented de novo CD20 + DLBC lymphoma with stage II, III or IV disease who have not have had prior cytotoxic chemotherapy or rituximab.
Treatment:
The chemotherapy, known as R-CHOP, will be administered by intravenous infusion every 21 days for a total of six times. If you receive DA-EPOCH-R, you will need to be in the hospital for your treatment. This treatment is given every 21 days for a total of six times.
Principal Investigator:
Enrollment Phone:
(708) 327-3223